A RANDOMIZED CONTROLLED TRIAL OF TOPICAL GLYCERYL TRINITRATE BEFORE TRANSRECTAL ULTRASONOGRAPHY-GUIDED BIOPSY OF THE PROSTATE

Background and aims Sublingual glyceryl trinitrate has been used as an aid to cannulate the Sphincter of Oddi during endoscopic retrograde cholangiopancreatography. Its role in terminal ileal intubation during colonoscopy is unknown. This study examines the role of sublingual glyceryl trinitrate in terminal ileal intubation during colonoscopy. Methods A triple-blind randomized controlled trial comparing sublingual glyceryl trinitrate (800 µg) vs. placebo (saline) in relation to terminal ileal intubation during colonoscopy was performed. Following caecal intubation, participants received sublingual glyceryl trinitrate/placebo followed by a 2-min observation period before intubation was attempted. Data on time to intubate the terminal ileum and intubation rate were collected. Results A total of 110 patients (age: 58 years (18–75)) were recruited and randomised as per protocol: 54 received sublingual glyceryl trinitrate. Terminal ileal intubation was successful in all patients receiving sublingual glyceryl trinitrate and in 53 (94.6%) of those receiving saline ( p = 0.243: Fischer’s exact). The median time taken for ileal intubation after application of spray was 72.5 (7–900) s in the glyceryl trinitrate group compared with 125 (5–900) s in the placebo group ( p = 0.150: Mann–Whitney). There were no major adverse events reported in either group. Conclusions Terminal ileal intubation rates and timing were very good in both groups. Routine sublingual glyceryl trinitrate was not proven to be beneficial in improving terminal ileal intubation or intubation success rates in the hands of experienced colonoscopists. However, trends in this small study might suggest that glyceryl trinitrate could be useful in the hands of less experienced colonoscopists or in difficult terminal ileal intubation cases.

Download Full-text

UP-02.137 A Randomized, Controlled Trial Comparing Lidocaine Periprostatic Nerve Block and Lidocaine Gel Intrarectally Associated with Tramadol Per Os for Transrectal Ultrasound Guided Biopsy of Prostate

Urology ◽

10.1016/j.urology.2011.07.955 ◽

2011 ◽

Vol 78 (3) ◽

pp. S307 ◽

Cited By ~ 2

Author(s):

S. Moudouni ◽

M. Amine ◽

A. Lakmichi ◽

Z. Dahami ◽

I. Sarf

Keyword(s):

Randomized Controlled Trial ◽

Nerve Block ◽

Controlled Trial ◽

Transrectal Ultrasound ◽

Ultrasound Guided ◽

Randomized Controlled ◽

Guided Biopsy ◽

Lidocaine Gel ◽

Periprostatic Nerve Block ◽

Ultrasound Guided Biopsy

Download Full-text

Rapid Intravenous Glyceryl Trinitrate in Ischemic Damage (RIGID) After Stroke: Rationale, Design and Protocol for a Prospective Randomized Controlled Trial

Frontiers in Neurology ◽

10.3389/fneur.2021.693330 ◽

2021 ◽

Vol 12 ◽

Author(s):

Lipeng Cai ◽

Gary Rajah ◽

Honglian Duan ◽

Jie Gao ◽

Zhe Cheng ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Glyceryl Trinitrate ◽

Intravenous Administration ◽

Controlled Trial ◽

Intravenous Thrombolysis ◽

Control Group ◽

Ischemic Damage ◽

Randomized Controlled ◽

Prospective Randomized Controlled Trial ◽

Intravenous Glyceryl Trinitrate

Background: Despite intravenous thrombolysis and endovascular therapy for acute ischemic stroke (AIS), many survivors still have varying degrees of disability. Glyceryl trinitrate (GTN), a nitric oxide (NO) donor, has been previously reported to induce neuroprotection after AIS. The use of GTN to reduce brain damage after stroke remains yet to be elucidated. This study was designed to explore the safety, feasibility, and preliminary efficacy of intravenous administration of GTN after AIS.Methods: A prospective randomized controlled trial is proposed with AIS patients. Participants will be randomly allocated to GTN group and control group with a 1:1 ratio (n = 40). Both groups will be treated with standard therapies according to the current stroke guidelines. Participants allocated to the GTN group will receive intravenous administration of GTN (5 mg GTN in 50 ml saline at a rate of 0.4 mg/h that is continued for 12.5 h/day for 2 days) within 24 h of symptom onset. Participants allocated to the control group will receive intravenous administration at equal capacity of 0.9% normal saline (NS) (total 50 ml/day at 4 ml/h that is continued for 12.5 h/day for 2 days). The primary outcome is safety [systolic blood pressure (SBP) <110 mmHg, headache], while the secondary outcomes include changes in functional outcome and infarction volume.Discussion: Rapid Intravenous Glyceryl Trinitrate in Ischemic Damage (RIGID) is a prospective randomized controlled trial that aims to ascertain the safety, feasibility, and preliminary efficacy of intravenous GTN as a neuroprotection strategy after AIS. These results will provide parameters for future studies as well as provide insights into treatment effects. Any possible neuroprotective qualities of GTN in AIS will also be elucidated.Trial Registration:www.chictr.org.cn, identifier: ChiCTR2100046271.

Download Full-text